All Clinical Trials

Clinical Trial NCT02101736

NF PROTOCOL 105, A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas in Subjects with Neurofibromatosis Type 1 in Children and Adults

  • ClinicalTrials.gov ID: NCT02101736
  • Recruiting participants (Starts Oct. 16, 2018)
  • Not accepting healthy volunteers
  • UTSW Principal Investigator: LAURA JEAN KLESSE

summary

neurofibromatosis type 1 (nF1), is a common human genetic disorder that affects approximately 100,000 people in the united States alone. individuals afflicted with nF1 develop a wide range of malignant and non-malignant manifestations. Plexiform neurofibromas are benign tumors of the nerve sheath that occur in approximately 40% of patients with nF1. They are a significant cause of morbidity in nF1 by causing pain, disfigurement or impairing function. Cabozantanib has emerged as a drug with significant impact on tumor volume, tumor apoptosis, and mast cell infiltration and as such has been selected for further clinical development.

objective

Primary aim: To estimate the objective response rate (oRR) as defined by 20% volumetric MRi response of the target lesion to cabozantinib at 12 months in children and adults with nF1 plexiform neurofibromas by volumetric MRi imaging.

If you are interested in this clinical trial, please contact Brittany Glass-Thomas on the Children’s Health Research Team.Call 214-456-4182Email